The impact of common pharmaceutical excipients on the gut microbiota.

IF 5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-06-18 DOI:10.1080/17425247.2023.2223937
Santhni Subramaniam, Srinivas Kamath, Amin Ariaee, Clive Prestidge, Paul Joyce
{"title":"The impact of common pharmaceutical excipients on the gut microbiota.","authors":"Santhni Subramaniam,&nbsp;Srinivas Kamath,&nbsp;Amin Ariaee,&nbsp;Clive Prestidge,&nbsp;Paul Joyce","doi":"10.1080/17425247.2023.2223937","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Increasing attention is being afforded to understanding the bidirectional relationships that exist between oral medications and the gut microbiota, in an attempt to optimize pharmacokinetic performance and mitigate unwanted side effects. While a wealth of research has investigated the direct impact of active pharmaceutical ingredients (APIs) on the gut microbiota, the interactions between inactive pharmaceutical ingredients (i.e. excipients) and the gut microbiota are commonly overlooked, despite excipients typically representing over 90% of the final dosage form.</p><p><strong>Areas covered: </strong>Known excipient-gut microbiota interactions for various classes of inactive pharmaceutical ingredients, including solubilizing agents, binders, fillers, sweeteners, and color additives, are reviewed in detail.</p><p><strong>Expert opinion: </strong>Clear evidence indicates that orally administered pharmaceutical excipients directly interact with gut microbes and can either positively or negatively impact gut microbiota diversity and composition. However, these relationships and mechanisms are commonly overlooked during drug formulation, despite the potential for excipient-microbiota interactions to alter drug pharmacokinetics and interfere with host metabolic health. The insights derived from this review will inform pharmaceutical scientists with the necessary design considerations for mitigating potential adverse pharmacomicrobiomic interactions when formulating oral dosage forms, ultimately providing clear avenues for improving therapeutic safety and efficacy.</p>","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1297-1314"},"PeriodicalIF":5.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425247.2023.2223937","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3

Abstract

Introduction: Increasing attention is being afforded to understanding the bidirectional relationships that exist between oral medications and the gut microbiota, in an attempt to optimize pharmacokinetic performance and mitigate unwanted side effects. While a wealth of research has investigated the direct impact of active pharmaceutical ingredients (APIs) on the gut microbiota, the interactions between inactive pharmaceutical ingredients (i.e. excipients) and the gut microbiota are commonly overlooked, despite excipients typically representing over 90% of the final dosage form.

Areas covered: Known excipient-gut microbiota interactions for various classes of inactive pharmaceutical ingredients, including solubilizing agents, binders, fillers, sweeteners, and color additives, are reviewed in detail.

Expert opinion: Clear evidence indicates that orally administered pharmaceutical excipients directly interact with gut microbes and can either positively or negatively impact gut microbiota diversity and composition. However, these relationships and mechanisms are commonly overlooked during drug formulation, despite the potential for excipient-microbiota interactions to alter drug pharmacokinetics and interfere with host metabolic health. The insights derived from this review will inform pharmaceutical scientists with the necessary design considerations for mitigating potential adverse pharmacomicrobiomic interactions when formulating oral dosage forms, ultimately providing clear avenues for improving therapeutic safety and efficacy.

常见药用辅料对肠道微生物群的影响。
引言:人们越来越关注了解口服药物和肠道微生物群之间存在的双向关系,试图优化药代动力学性能并减轻不必要的副作用。尽管大量研究调查了活性药物成分(API)对肠道微生物群的直接影响,但非活性药物成分和肠道微生物群之间的相互作用通常被忽视,尽管赋形剂通常占最终剂型的90%以上。涵盖的领域:详细综述了各类非活性药物成分的已知赋形剂-肠道微生物群相互作用,包括增溶剂、粘合剂、填料、甜味剂和着色剂。专家意见:明确的证据表明,口服药用辅料与肠道微生物直接相互作用,可以对肠道微生物群的多样性和组成产生积极或消极的影响。然而,尽管赋形剂-微生物群相互作用可能改变药物药代动力学并干扰宿主代谢健康,但在药物配制过程中,这些关系和机制通常被忽视。这篇综述得出的见解将为制药科学家在配制口服剂型时提供必要的设计考虑,以减轻潜在的不良药物-微生物相互作用,最终为提高治疗安全性和疗效提供明确的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.10
自引率
3.00%
发文量
104
审稿时长
3 months
期刊介绍: Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信